{
  "acst1": {
    "study_name": "ACST-1 (Asymptomatic Carotid Surgery Trial 1)",
    "publication_year": "2010 (10-year results)",
    "study_period": "1993-2004",
    "participants": 3120,
    "intervention": "CEA vs Medical Therapy",
    "follow_up": "10 years",
    "key_findings": {
      "cea_10_year_stroke_risk": "10.8%",
      "medical_10_year_stroke_risk": "16.9%",
      "perioperative_risk": "3%",
      "absolute_risk_reduction": "~6%",
      "benefit_primarily_in": "Patients ≤75 years",
      "women_benefit": "Later than men but significant"
    },
    "risk_stratification": {
      "age_threshold": "75 years",
      "life_expectancy_required": "≥5 years",
      "stenosis_threshold": "≥60%"
    }
  },
  "acst2": {
    "study_name": "ACST-2 (Asymptomatic Carotid Surgery Trial 2)",
    "publication_year": "2021",
    "study_period": "2008-2020",
    "participants": 3625,
    "intervention": "CAS vs CEA",
    "follow_up": "Mean 5 years",
    "key_findings": {
      "cas_30day_risk_disabling_stroke_death": "1.0%",
      "cea_30day_risk_disabling_stroke_death": "0.9%",
      "cas_5year_risk_disabling_stroke_death": "3.4%",
      "cea_5year_risk_disabling_stroke_death": "3.5%",
      "cas_5year_any_stroke": "8.6%",
      "cea_5year_any_stroke": "7.1%",
      "conclusion": "Both procedures comparable"
    }
  },
  "cea8": {
    "score_name": "CEA-8 Clinical Risk Score",
    "purpose": "Predict 30-day stroke/death risk after CEA in asymptomatic patients",
    "development_cohort": "6553 Medicare patients in New York State",
    "risk_factors": [
      {
        "factor": "Female",
        "points": 1,
        "OR": 1.47,
        "CI": "1.11-1.94"
      },
      {
        "factor": "Non-White",
        "points": 1,
        "OR": 1.82,
        "CI": "1.14-2.93"
      },
      {
        "factor": "Distant stroke or TIA",
        "points": 1,
        "OR": 1.48,
        "CI": "1.08-2.03"
      },
      {
        "factor": "Non-operated stenosis ≥50%",
        "points": 1,
        "OR": 1.76,
        "CI": "1.32-2.34"
      },
      {
        "factor": "Congestive heart failure",
        "points": 1,
        "OR": 1.63,
        "CI": "1.09-2.43"
      },
      {
        "factor": "Coronary artery disease",
        "points": 1,
        "OR": 1.59,
        "CI": "1.15-2.19"
      },
      {
        "factor": "Valvular heart disease",
        "points": 1,
        "OR": 1.54,
        "CI": "1.04-2.27"
      },
      {
        "factor": "Severe disability",
        "points": 2,
        "OR": 3.71,
        "CI": "1.78-7.74"
      }
    ],
    "risk_categories": {
      "low_risk": {
        "points": "0-2",
        "predicted_risk": "0.6-2.8%"
      },
      "moderate_risk": {
        "points": "3",
        "predicted_risk": "4.7%"
      },
      "high_risk": {
        "points": "≥4",
        "predicted_risk": "7.5-9.6%"
      }
    }
  },
  "esvs_2023": {
    "guideline": "ESVS 2023",
    "purpose": "Identify asymptomatic patients at higher risk of stroke on medical therapy",
    "clinical_features": [
      {
        "factor": "Contralateral TIA/Stroke",
        "OR": 3.0,
        "description": "History of contralateral cerebrovascular events"
      },
      {
        "factor": "Age considerations",
        "description": "Benefits primarily in patients ≤75 years (from ACST-1)"
      },
      {
        "factor": "Life expectancy",
        "requirement": "≥5 years"
      }
    ],
    "imaging_features": [
      {
        "factor": "Silent ipsilateral infarction on CT",
        "OR": 3.0
      },
      {
        "factor": "Stenosis progression >20%",
        "OR": 1.92
      },
      {
        "factor": "Large plaque area >80 mm²",
        "OR": 5.81
      },
      {
        "factor": "Intraplaque hemorrhage on MRI",
        "OR": 3.66
      },
      {
        "factor": "Impaired cerebral vascular reserve",
        "OR": 6.14
      },
      {
        "factor": "Plaque echolucency",
        "OR": 2.61
      },
      {
        "factor": "Spontaneous microembolization",
        "OR": 7.46
      },
      {
        "factor": "Microembolization + echolucent plaque",
        "OR": 10.61
      }
    ],
    "intervention_threshold": {
      "stenosis": "60-99%",
      "five_year_stroke_risk": ">10%",
      "perioperative_risk": "<3%"
    }
  },
  "acsrs": {
    "study_name": "ACSRS (Asymptomatic Carotid Stenosis and Risk of Stroke)",
    "purpose": "Natural history study of asymptomatic carotid stenosis",
    "participants": 1121,
    "key_findings": {
      "annual_stroke_risk_range": "0.2% to 8.7% with 50-79% stenosis",
      "annual_stroke_risk_severe": "0.5% to 17.3% with 80-99% stenosis",
      "high_risk_plaque_criteria": "Juxtaluminal black area ≥8 mm²",
      "high_risk_annual_stroke_rate": "4.1%",
      "high_risk_population": "21% of cohort contained 86% of strokes"
    },
    "risk_factors": [
      "Baseline degree of stenosis",
      "History of contralateral stroke or TIA",
      "Juxtaluminal black area ≥8 mm² without echogenic cap",
      "Discrete white areas in hypoechoic plaque"
    ]
  }
}